CoChat

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

Open access
Heise, Tim, Mathieu, Chantal · 2017 · Diabetes, Obesity and Metabolism
Cited by 106

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Manufacturers of insulin products for diabetes therapy have long sought ways to modify the absorption rate of exogenously administered insulins in an effort to better reproduce the naturally occurring pharmacokinetics of endogenous insulin secretion. Several mechanisms of protraction have been used in pursuit of a basal insulin, for which a low injection frequency would provide tolerable and reproducible glucose control; these mechanisms have met with varying degrees of success. Before the advent of recombinant DNA technology, development focused on modifications to the formulation that increased insulin self‐association, such as supplementation with zinc or the development of preformed precipitates using protamine. Indeed, NPH insulin remains widely used today despite a frequent need for a twice‐daily dosing and a relatively high incidence of hypoglycaemia. The early insulin analogues used post‐injection precipitation (insulin glargine U100 ) or dimerization and albumin binding (insulin detemir) as methods of increasing therapeutic duration. These products approached a 24‐hour glucose‐lowering effect with decreased variability in insulin action. Newer basal insulin analogues have used up‐concentration in addition to precipitation (insulin glargine U300 ), and multihexamer formation in addition to albumin binding (insulin degludec), to further increase duration of action and/or decrease the day‐to‐day variability of the glucose‐lowering profile. Clinically, the major advantage of these recent analogues has been a reduction in hypoglycaemia with similar glycated haemoglobin control when compared with earlier products. Future therapies may bring clinical benefits through hepato‐preferential insulin receptor binding or very long durations of action, perhaps enabling once‐weekly administration and the potential for further clinical benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12782

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 106

Metadata

Authors
Heise, T., & Mathieu, C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-09-26
Volume
19
Issue
1
Pages
3-12
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2520301979
Cited by
106
References
18
FWCI
11.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. https://app.cochat.ai/papers/10.1111/dom.12782
The paper
Heise, T., & Mathieu, C. (2017). Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12782

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.